Capital International Ltd. CA Acquires 9,258 Shares of Illumina, Inc. $ILMN

Capital International Ltd. CA raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 16.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 64,849 shares of the life sciences company’s stock after buying an additional 9,258 shares during the quarter. Capital International Ltd. CA’s holdings in Illumina were worth $6,159,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Assetmark Inc. boosted its position in shares of Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after acquiring an additional 96 shares during the period. Versant Capital Management Inc raised its stake in Illumina by 8.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after purchasing an additional 111 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares during the period. Archer Investment Corp grew its position in Illumina by 12.9% in the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after purchasing an additional 123 shares during the last quarter. Finally, Callan Family Office LLC increased its holdings in shares of Illumina by 4.4% during the 3rd quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after purchasing an additional 124 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

ILMN stock opened at $124.28 on Tuesday. The business’s fifty day moving average is $134.17 and its 200-day moving average is $119.55. The company has a market cap of $19.00 billion, a P/E ratio of 22.80, a price-to-earnings-growth ratio of 2.38 and a beta of 1.45. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter in the previous year, the company earned $0.95 earnings per share. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ILMN. Piper Sandler lowered their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. UBS Group reiterated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Stifel Nicolaus increased their price target on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, Barclays lifted their price objective on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $129.69.

Insider Activity at Illumina

In related news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is currently owned by insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.